This article is for people who have metastatic melanoma, their care partners, and others who want to learn about immunotherapy. This activity is intended for oncologists, dermatologists, pathologists, and healthcare practitioners who care for patients with metastatic melanoma. The goal of this activity is to educate clinicians in the practical application of recently approved systemic.
Upon completion of this activity, participants will be able to:
Select opitmal therapy for patients with metastatic melanoma that harbors v600 BRAF mutations and for patients with wild-type BRAF. Explain the role of immunotherapy in patients with V600 BRAF mutation-positive metastatic melanoma. Outline a sequential treatment strategy for patients with V600 BRAF mutation-positive metastatic melanoma. Describe how to manage side effects and assess response to immunotherapy and targeted therapy in patients being treated for metastatic melanoma.
Approximate Time to Complete: 15 minutes
Course Available Beginning: Oct. 19, 2016
Developed through a partnership between SITC and Medscape.
 |
 |